Navigation Links
SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
Date:5/13/2008

development and commercialization, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to file INDs or commence IND enabling activities or preclinical or clinical studies in the referenced time frames. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or future clinical trials. In addition, results may be affected by the initiation, implementation and conclusion of its collaborations, cash generated or used in connection with new or existing collaborations, the failure to successfully complete collaborations or partnerships or enter into new collaborations on any of its research and development programs, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, the level of resources that its collaborative partners devote to development of its product candidates, the scope and validity of patent protection for its products, and its ability to obtain additional funding to support its operations. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10- K for the year ended December 31, 2007, as well as other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances after the dat
'/>"/>
SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 According to a ... & 2D Gel Electrophoresis, Agarose & Polyacrylamide Gel, Capillary ... by Application & by End User - Global Forecast ... expected to reach around $1.98 Billion by 2020 with ... to 2020. Browse 226 ma ...
(Date:5/22/2015)... 2015 Knowledgent , the data ... explores the potential of big data analytics in the ... developed to help life sciences and healthcare organizations understand ... gain critical business insights. , The life sciences and ... driven by patient profiling, compliance and regulatory requirements, and ...
(Date:5/21/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... develops and commercializes proprietary technologies and products for advanced ... for the second fiscal quarter ended March 31, 2015. ... to advance business with our existing customers and to ... and CEO of SQI. "The delivery of a fully ...
(Date:5/21/2015)... May 21, 2015 Specialty Pharmacy ... and been admitted to BPA Worldwide as a ... will track audience data for Specialty Pharmacy Times ... , “By becoming a member of BPA Worldwide, ... providing our clients with the most reliable, unequaled ...
Breaking Biology Technology:Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Specialty Pharmacy Times Joins BPA Worldwide 2
... , LONDON, November 9 ... US Food and Drug Administration (FDA), privately,owned UK company ... its innovative,anti-inflammatory agent AIMSPRO(R) has been awarded an Orphan-Drug,designation ... ALS, also known as Lou ...
... , LYNBROOK, N.Y., Nov. 6 BioSpecifics Technologies Corp. ... collagenase-based products, today announced its financial results for the ... were extremely happy that, in September of this year, ... vote of 12-0, the approval of XIAFLEX(TM) for the ...
... announced today that it has been awarded a Small Business ... Medical Research and Material command. Under terms of the agreement, ... of Dengue virus. , Dengue virus is ... forces deployed to tropical areas of the world. Due to ...
Cached Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
... in partnership with Rothamsted Research have officially joined forces ... how can we sustainably feed a growing population? ... the House of Commons on 26 October amidst reports ... reaching seven billion. The Alliance brings together world-class ...
... 28 2011 the research icebreaker Polarstern sets off on ... from research institutions in 14 countries will take part ... wide variety of topics: oceanography and marine chemistry, atmospheric ... animals all the way to crustaceans, fish and whales. ...
... luxuriously thick winter coat, reindeer are perfectly prepared for the ... just keep the cold out, it keeps the warmth in ... what happens when they are active and generating heat? Usain ... do exercising reindeer avoid overheating? Arnoldus Blix from the University ...
Cached Biology News:UK scientists come together to help feed the 7 billion 2UK scientists come together to help feed the 7 billion 3UK scientists come together to help feed the 7 billion 4UK scientists come together to help feed the 7 billion 5RV Polarstern launches 28th Antarctic season 2Rudolph the red-nosed reindeer's cooling strategy revealed 2
... SMZ line is a Greenough stereomicroscope designed for ... is available with a choice of a large ... base (N2GG). This microscope can be easily connected ... at the same time giving you ultimate flexibility. ...
... siRNA applications, contains magnetic nanoparticles (MagTag) which ... of interest. Exploiting magnetic force the full ... towards and delivered into the target cells ... be used for adherent cells; for suspension ...
...
... TNT Coupled Reticulocyte Lysate Systems(a,b,c,d) offer ... vitro translations: a single-tube, coupled transcription/translation ... simplify the process and reduce the ... translation results. Standard rabbit reticulocyte lysate ...
Biology Products: